Indication | Follicular lymphoma [ICD11 code: 2B50.Z]
---|---
INN | Bendamustine
Medicine type | Chemical agent
List type | Complementary
Formulations | Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
EML status history | First added in 2015 (TRS 994)
Sex | All
Age | Adolescents and adults
Therapeutic alternatives | The recommendation is for this specific medicine
Patent information | Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org. Read more about patents.

Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, bendamustine was added to the complementary list of the EML for use in treatment protocols for follicular lymphoma. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for follicular lymphoma is attached.